Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression
A Tanimoto, S Matsumoto, S Takeuchi, S Arai… - Clinical Cancer …, 2021 - AACR
Purpose: In ALK-rearranged non–small cell lung cancer (NSCLC), impacts of concomitant
genetic alterations on targeted therapies with ALK-tyrosine kinase inhibitors (ALK-TKI) are …
genetic alterations on targeted therapies with ALK-tyrosine kinase inhibitors (ALK-TKI) are …
Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non–Small-Cell Lung Cancer
E Pailler, V Faugeroux, M Oulhen, L Mezquita… - Clinical Cancer …, 2019 - AACR
Purpose: Patients with anaplastic lymphoma kinase (ALK)–rearranged non–small-cell lung
cancer (NSCLC) inevitably develop resistance to ALK inhibitors. New diagnostic strategies …
cancer (NSCLC) inevitably develop resistance to ALK inhibitors. New diagnostic strategies …
[HTML][HTML] Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
A Kron, C Alidousty, M Scheffler, S Merkelbach-Bruse… - Annals of oncology, 2018 - Elsevier
Background We analyzed whether co-occurring mutations influence the outcome of systemic
therapy in ALK-rearranged non-small-cell lung cancer (NSCLC). Patients and methods ALK …
therapy in ALK-rearranged non-small-cell lung cancer (NSCLC). Patients and methods ALK …
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
MR Yun, HM Choi, YW Lee, HS Joo… - EMBO molecular …, 2019 - embopress.org
Clinical benefit of ALK tyrosine kinase inhibitors (ALK‐TKI s) in ALK‐rearranged lung cancer
has been limited by the inevitable development of acquired resistance, and bypass …
has been limited by the inevitable development of acquired resistance, and bypass …
Relevance of detection of mechanisms of resistance to ALK inhibitors in ALK-rearranged NSCLC in routine practice
P Jamme, C Descarpentries, R Gervais, E Dansin… - Clinical Lung Cancer, 2019 - Elsevier
Background Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have
shown efficacy in the treatment of ALK-rearranged non–small-cell lung cancer (NSCLC), but …
shown efficacy in the treatment of ALK-rearranged non–small-cell lung cancer (NSCLC), but …
Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung …
K Tanimura, T Yamada, M Horinaka, Y Katayama… - Cancer Letters, 2021 - Elsevier
Anaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKIs) have improved clinical
outcomes in non-small cell lung cancer (NSCLC) harboring ALK-rearrangements. However …
outcomes in non-small cell lung cancer (NSCLC) harboring ALK-rearrangements. However …
Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer
Objectives ALK tyrosine kinase inhibitors (TKIs), including crizotinib and several next
generation TKIs, have demonstrated beneficial clinical outcomes in ALK-positive non-small …
generation TKIs, have demonstrated beneficial clinical outcomes in ALK-positive non-small …
Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
M Oulhen, P Pawlikowska, T Tayoun, M Garonzi… - NPJ Precision …, 2021 - nature.com
Gatekeeper mutations are identified in only 50% of the cases at resistance to Anaplastic
Lymphoma Kinase (ALK)-tyrosine kinase inhibitors (TKIs). Circulating tumor cells (CTCs) are …
Lymphoma Kinase (ALK)-tyrosine kinase inhibitors (TKIs). Circulating tumor cells (CTCs) are …
Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK‐rearranged non‐small‐cell lung cancer
P Song, F Zhang, Y Li, G Yang, W Li, J Ying… - Cancer …, 2019 - Wiley Online Library
Background TP53 mutations are the most prevalent mutations detected in non‐small‐cell
lung cancer (NSCLC) and have been revealed as a negative prognostic biomarker of …
lung cancer (NSCLC) and have been revealed as a negative prognostic biomarker of …
The landscape of ALK-rearranged non-small cell lung cancer: A comprehensive review of clinicopathologic, genomic characteristics, and therapeutic perspectives
V Cognigni, F Pecci, A Lupi, G Pinterpe, C De Filippis… - Cancers, 2022 - mdpi.com
Simple Summary In recent years, prognosis of non-small cell lung cancer (NSCLC) patients
significantly improved thanks to the introduction of tyrosine kinase inhibitors (TKIs) in clinical …
significantly improved thanks to the introduction of tyrosine kinase inhibitors (TKIs) in clinical …